Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KHNYN (KH and NYN domain-containing protein) is a multidomain endoribonuclease that functions as a cofactor for the zinc finger antiviral protein (ZAP). The protein contains a KH-like domain (which, unlike classical KH domains, does not robustly bind RNA but may interface with other proteins) and a NYN domain that confers catalytic activity required for the degradation of viral RNA. KHNYN is essential for ZAP-mediated antiviral activity and restricts infection by viruses such as HIV and SARS-CoV-2, supporting the cellular antiviral response. Unlike canonical KH domains, the KHNYN KH domain is evolutionarily divergent and primarily serves as a protein-protein interaction site rather than an RNA-binding module. KHNYN is not currently targeted by any drugs, nor used as a biomarker or has known therapeutic safety concerns. Its disease role is mainly related to host defense against viral infection.
Mechanism for biological function involves endonucleolytic cleavage (via NYN domain) and facilitating ZAP-mediated RNA degradation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KH and NYN domain-containing protein (KHNYN).